Stomach Cancer Market to reach USD 6.5 Billion by 2026 at a CAGR of 5.7%

Introduction

Stomach Cancer is an aggressive form of malignancy that spreads in the stomach. The expansion of gastric cancer is a complex and multifactorial process that involves etiological and epigenetic alterations. Most commonly, this cancer develops in the pyloric area of the stomach. A study suggests that men are more prone to gastric cancer than women. Gastric lymphomas, neuroendocrine tumors, and gastrointestinal stromal tumors are some of the major types of gastric cancer.  They are mostly caused by smoking, H. pylori infection, and occupational diseases regardless of the genetic makeup of the person. In July 2012, European Commission granted orphan drug designation to Ramucirumab for gastric cancer treatment.

In accordance to the Cancer Research U.K., around 44% of men survive gastric cancer for at least once in a year, and the number is likely to fall to 20% for five years. On the global scale, prevalence of stomach cancer is less common in the eastern European regions but highest in East Asia and the Asia Pacific regions. For instance, Korean countries are housing one of the highest populations of stomach cancer with (39.6 per 100,000), followed by Mongolia with (33.1 per 100,000), and Japan with (27.5 per 100,000). In East Asia, the average incidence of gastric cancer is 32.1 per 100,000 among men, and 13.2 among women, NIH. This cancer is more prevalent among the age group of 60 to 80 years. According to American Institute of Cancer Research there were 1 million new cases of stomach cancer in 2018.

Segmental Analysis

Global stomach cancer market is segmented by therapy, end-users, and regions.

By therapy, the stomach cancer market is segmented into chemotherapy, surgical therapy, target therapy, and others.  Targeted drug therapy has the potential to kill malignant cells and increase survival rates. FDA has approved several targeted therapeutics agents because of their less adverse effects, which is expected to flourish the segmental growth during the forecast period. Besides, targeted drugs such as imatinib and sunitinib, regorafenib, and Trastuzumab are commonly used to treat (GIST) gastrointestinal stromal tumors. In the U.S. alone, there are around 3000 to 6000 new cases of GIST diagnosed every year, National Cancer Institute.Separated from this, F. Hoffmann La Roche designed Trastuzumab (Herceptin) a type of targeted therapy targeting HER2 for gastric cancer.

Based on end-users, the stomach cancer market is segmented into hospital and specialty clinics, cancer research & treatment centers, and others.

Hospitals and specialty clinics segments are leading the market following the increasing prevalence of H. pylori infection. As per statistics provided by CDC, H. pylori infection causes more than 90% of duodenal ulcers and 80% of stomach ulcers, and approximately 25 million Americans are prone to suffer from peptic ulcers once in their lifetime. Additionally, 500,000 to 850,000 new cases of peptic ulcers disease and more than 1 million ulcer related hospitalizations are recorded every year in the U.S. The country witnessed around 20,249 hospital admissions for malignant neoplasm of stomach, with 25,605 finished consultant (FCI) incidences resulting in 62,477 FCE bed days in 2017, by National Institute for Health and Research.

Regional Analysis

Geographically, the global stomach cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).

Asia Pacific is housing a huge geriatric population suffering from stomach cancer. Also, the region has one of the highest mortalities rates when it comes to stomach cancer-related deaths. In 2018, the region witnessed 584375 deaths around 74.7% of the global total. According to the regional classification, 619226 men and 428298 women were diagnosed with stomach cancer in 2018.

In Europe, the prevalence of stomach cancer is increasing at an alarming rate, which, in turn, is unlocking several opportunities for the stomach cancer market in the region. According to ECIS (EU28), stomach cancer was accounted to be the 13^th most commonly diagnosed cancer, and 7^th most common cause for deaths in Europe. In 2018, 80,000 new cancer cases were recorded in the EU.

Competitive Players

1. Merck & Co. Inc.
2. GlaxoSmithKline plc
3. CareFusion
4. Apotex Inc.
5. Sanofi
6. Takeda Pharmaceutical Company Limited
7. Pfizer Inc.
8. Eli Lilly and Company
9. Dr. Reddy’s Laboratories Ltd.

Recent Developments

• October 2023- Phanes, in partnership with Keytruda manufacturer Merck, entered into a supply agreement and clinical trial collaboration. Currently, patients are enrolled in a phase 1 clinical trial to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of PT886 in patients diagnosed with locally advanced or metastatic gastric, GEJ, or pancreatic cancer.
• November 2023- The FDA approved Merck's Keytruda in combination with chemotherapy as the first treatment for adult patients with gastric cancer.

Segmentation

1. By Type
   1. Adenocarcinoma
   2. Lymphoma
   3. Gastrointestinal Stromal Tumor
   4. Carcinoid Tumor
   5. Others
2. By Therapy Type
   1. Chemotherapy 
   2. Targeted Therapy 
   3. Immunotherapy 
   4. Radiation Therapy 
   5. Surgery 
3. By End-User
   1. Ambulatory Surgery Centers 
   2. Hospitals and Specialty Clinics 
   3. Other End-Users